Overview
- Third-quarter revenue came in at about $598.9 million versus roughly $580.2 million expected, while diluted EPS was $0.06 versus a $0.09 consensus.
- Hims said it is in active discussions to offer Wegovy injections and a potential oral version through its platform, with the oral option pending regulatory approval.
- Subscribers reached about 2.47 million, up roughly 21% year over year, and monthly online revenue per average subscriber rose 19% to $80.
- The company guided fourth-quarter revenue to $605 million–$625 million and narrowed full-year 2025 revenue to $2.335 billion–$2.355 billion.
- Shares gained more than 5% in after-hours trading as Hims highlighted expansion into GLP‑1 options, testosterone and menopause treatments, new lab-testing capacity, and international growth through Zava and a planned 2026 Canada launch for generic GLP‑1 shots.